- Home
- IKNA vs ARTV Comparison
IKNA vs ARTV Comparison
Compare IKNA & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- ARTV
- Stock Information
- Founded
- IKNA 2016
- ARTV 2019
- Country
- IKNA United States
- ARTV United States
- Employees
- IKNA N/A
- ARTV N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- ARTV
- Sector
- IKNA Health Care
- ARTV
- Exchange
- IKNA Nasdaq
- ARTV NYSE
- Market Cap
- IKNA 61.8M
- ARTV 61.9M
- IPO Year
- IKNA 2021
- ARTV 2024
- Fundamental
- Price
- IKNA $1.11
- ARTV $2.24
- Analyst Decision
- IKNA Buy
- ARTV Strong Buy
- Analyst Count
- IKNA 2
- ARTV 7
- Target Price
- IKNA $3.00
- ARTV $20.00
- AVG Volume (30 Days)
- IKNA 84.2K
- ARTV 679.3K
- Earning Date
- IKNA 05-12-2025
- ARTV 05-22-2025
- Dividend Yield
- IKNA N/A
- ARTV N/A
- EPS Growth
- IKNA N/A
- ARTV N/A
- EPS
- IKNA N/A
- ARTV N/A
- Revenue
- IKNA N/A
- ARTV $251,000.00
- Revenue This Year
- IKNA N/A
- ARTV N/A
- Revenue Next Year
- IKNA N/A
- ARTV N/A
- P/E Ratio
- IKNA N/A
- ARTV N/A
- Revenue Growth
- IKNA N/A
- ARTV N/A
- 52 Week Low
- IKNA $0.97
- ARTV $1.78
- 52 Week High
- IKNA $1.94
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- IKNA 38.47
- ARTV N/A
- Support Level
- IKNA $1.06
- ARTV N/A
- Resistance Level
- IKNA $1.25
- ARTV N/A
- Average True Range (ATR)
- IKNA 0.10
- ARTV 0.00
- MACD
- IKNA 0.00
- ARTV 0.00
- Stochastic Oscillator
- IKNA 39.83
- ARTV 0.00
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).